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doi:10.1Objectives: The surgical approach to ischemic cardiomyopathy maximizing survival remains a dilemma, with
decisions complicated by secondary mitral regurgitation, ventricular remodeling, and heart failure. As a compo-
nent of decision support, we sought to develop prediction models for comparing survival after coronary artery
bypass grafting alone, coronary artery bypass grafting plus mitral valve anuloplasty, coronary artery bypass graft-
ing plus surgical ventricular restoration, and listing for cardiac transplantation.
Methods: From 1997 to 2007, 1468 patients with ischemic cardiomyopathy (ejection fraction<30%) underwent
coronary artery bypass grafting alone (n ¼ 386), coronary artery bypass grafting plus mitral valve anuloplasty (n
¼ 212), coronary artery bypass grafting plus surgical ventricular restoration (n¼ 360), or listing for cardiac trans-
plantation (n¼ 510). Mean follow-up was 3.8 2.8 years, with 5577 patient-years of data available for analysis.
Risk factors were identified for early and late mortality by using 80% training and 20% validation sets. Outcomes
were calculated for each applicable strategy to identify which maximized predicted 5-year survival. Models were
programmed as a strategic decision-support tool.
Results:One-, 5-, and 9-year survival were as follows, respectively: coronary artery bypass grafting, 92%, 72%,
and 53%; coronary artery bypass grafting plus mitral valve anuloplasty, 88%, 57%, and 34%; coronary artery
bypass grafting plus surgical ventricular restoration, 94%, 76%, and 55%; and listing for cardiac transplantation,
79%, 66%, and 54%. Risk factors included older age, higher New York Heart Association class, lower ejection
fraction, longer interval from myocardial infarction to operation, and numerous comorbidities. Predicted and ob-
served survivals in validation groups were similar (P> .1). Patient-specific simultaneous solutions of applicable
models revealed therapy potentially providing maximum survival benefit. Coronary artery bypass grafting alone
and listing for cardiac transplantation often maximized 5-year survival; only 15% of patients undergoing coro-
nary artery bypass grafting plus mitral valve anuloplasty were predicted to fare best with this therapy.
Conclusion:Validated predictionmodels can aid surgeons in recommending personalized treatment plans thatmax-
imize short- and long-term survival for ischemic cardiomyopathy. (J Thorac Cardiovasc Surg 2010;139:283-293)Supplemental material is available online.With multiple surgical therapies for ischemic cardiomyop-
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The Journal of Thoracic and Camizes survival for a given patient often remains a dilemma.
These therapies include coronary artery bypass grafting
(CABG) alone when there is viable, perhaps hibernating
myocardium; CABG with mitral valve (MV) anuloplasty
(MVA) when severe chronic secondary mitral regurgitation
(MR) accompanies ischemic disease; CABG with surgical
ventricular restoration (SVR; the Dor procedure1) when
the anterior myocardium is akinetic or dyskinetic; and list-
ing for cardiac transplantation (LCTx) when alternative
interventions might not ameliorate the circumstances.
What is needed is a personalized strategic algorithm and de-
cision aid to assist surgeons in recommending a therapy and
patients in making an informed decision.
The purposes of this study were to (1) develop and vali-
date comparative prediction models of survival after these
4 surgical interventions, (2) calculate how many patients
are predicted to experience better survival after an applicable
therapy other than the one received, and (3) transform these
models into a computer-based strategic decision aid for
facilitating personalized decision making.rdiovascular Surgery c Volume 139, Number 2 283
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
LCTx ¼ listing for cardiac transplantation
MR ¼ mitral regurgitation
MV ¼ mitral valve
MVA ¼ mitral valve anuloplasty
NYHA ¼ New York Heart Association
SVR ¼ surgical ventricular restoration




From 1997 to 2007, 1468 patients were surgically treated for ischemic
cardiomyopathy at Cleveland Clinic. Ischemic cardiomyopathy was defined
as severe left ventricular systolic dysfunction with a measured or estimated
ejection fraction of less than 30%, as determined by ventriculographic or
echocardiographic analysis. Of these patients, 386 underwent CABG alone,
212 CABGþMVA, 360 CABGþSVR, and 510 LCTx. All patients not listed
for transplantation and 88% of the LCTx group had a documented remote
(>30 days) myocardial infarction. Most patients had multisystem coronary
artery disease and multiple noncardiac comorbidities (Table 1).
Data
Clinical, angiographic, and electrocardiographic variables and details of
the surgical procedures were obtained from prospective clinical cardiovas-
cular information registries maintained concurrently with patient care. All
data were approved for use in research by the institutional review board,
with patient consent waived.
Myocardial viability, an important factor in identifying applicable ther-
apies, was assessed by using delayed hyperenhancement cardiac magnetic
resonance imaging after administering a gadolinium-based contrast agent
in 153 patients, dobutamine echocardiographic analysis in 111 patients, flu-
orodeoxyglucose positron emission tomographic analysis in 15 patients,
99-mTc–single photon emission computed tomographic analysis in 11
patients, and thallium stress studies in 7 patients (Table E1). Availability
of data was strongly associated with therapy received, with the majority
of these tests performed in the CABGþSVR group. Thus, data were insuf-
ficient from these multiple modalities to formulate a single viability score
and model its influence on survival.
End Point
The primary end point for developing the decision aid was all-cause
time-related mortality, including in-hospital mortality after surgical proce-
dures and interim deaths while awaiting transplantation (Table E2). Patients
were followed routinely with consent. This active follow-up was supple-
mented with passive data using the Social Security Death Index,2,3 with
a common closing date of February 16, 2007. Mean duration of follow-up
was 3.8  2.8 years, and 5577 patient-years of follow-up were available
for analysis. Among survivors, 25%were followed for more than 6.8 years,
and 10% were followed for more than 8.7 years. Survival estimates were
considered reliable to 9 years.
Data Analysis
Brief summary. Using a random 80% training dataset, multivariable
analysis of mortality was performed for each therapy (therapy-specific anal-
ysis) based solely on preoperative variables (Appendix 1).4-6 Therapy-spe-
cific analyses were performed because each exhibited a different temporal
pattern of risk of death (hazard function, Figure E1) because some risk fac-
tors were more prominently associated with mortality in one group and less284 The Journal of Thoracic and Cardiovascular Surgso in another. Having developed therapy-specific risk-factor models, all var-
iables appearing in any of the 4 models were incorporated into 4 final train-
ing models, all with a common set of predictors, regardless of statistical
significance (semisaturated models).
Because the objective of the study was not to compare survival of
groups of similar patients but rather to predict survival for an individu-
al’s personal characteristics and condition, we deliberately did not adjust
the prediction models for selection factors (eg, by using propensity
scores).7
For validation, the 4 training models were used to predict survival of
each patient in the 20% hold-out data set. Two validation criteria were
used: (1) comparing the number of observed deaths versus predicted deaths8
and (2) comparing observed versus predicted survival.9 Thereafter, final
semisaturated decision-support models for each therapy were formulated
by using all the data (see the online Methods section for details of model de-
velopment and validation).
Survival comparison. To investigate whether the therapy received
maximized survival, we predicted 5-year survival after each therapy for
each patient. However, not all therapies are applicable to a given patient,
and therefore general clinical criteria were used to select by automated
means the comparisons deemed applicable. A major factor used clinically
to identify applicable therapies is the presence of ischemic symptoms (an-
gina) and the presence of viable myocardium in territories with diseased
but bypassable coronary arteries (Figure 1). Because of the paucity of via-
bility data, with the data available, we were able to incompletely assess
the applicability of CABG. For patients without such studies, we used the
American College of Cardiology/American Heart Association guidelines
for applicability of CABG based on angina and coronary artery disease.10
Thus, we considered 1082 (74%) patients to be eligible for CABG alone,
598 (41%) for CABGþMVA when 3þ/4þMR was present, 742 (50%) for
CABGþSVR when anterior wall akinesia or dyskinesia was present and
left ventricular end-diastolic diameter was greater than 6.0 cm, and 671
(46%) for transplantation when age was less than 70 years, NewYork Heart
Association (NYHA) functional class was III/IV, and creatinine level was
less than 1.7 mg$dL1.
Presentation. Continuous variables are summarized as means  stan-
dard deviations and as 15th, 50th (median), and 85th percentiles when
values were skewed, which is consistent with 1 standard deviation. Com-
parisons used the Kruskal–Wallis test. Categorical data are summarized by
frequencies and percentages. Comparisons used the c2 test. Uncertainty is
expressed by 68% confidence limits, which is consistent with 1 standard
error. All analyses were performed with SAS statistical software (SAS ver-
sion 9.1; SAS Institute, Inc, Cary, NC).
Decision-support Tool
We developed a java-based user interface that used these hazard-based
models to predict individual patient survival curves for applicable therapies
based on PROC HAZARD, which is described at http://www.
clevelandclinic.org/heartcenter/hazard. This application accepts individual
patient characteristics for each variable in the models as inputs, allowing
surgeons to compare the resulting survival curves predicted for each
applicable therapy or investigate how individual characteristics affect
prognosis.RESULTS
Survival and Risk-factor Models
After CABG alone, unadjusted survival at 1, 3, 5, and 9
years was 92%, 82%, 72%, and 53%, respectively (Fig-
ure 2). Risk factors included NYHA functional class III/IV
for early death and multiple noncardiac comorbidities for
late death (Table 2). After CABGþMVA, unadjusted sur-
vival at 1, 3, 5, and 9 years was 88%, 72%, 57%, andery c February 2010
TABLE 1. Patient characteristics by surgical therapy
CABG alone (total n ¼ 386) CABGþMVA (total n ¼ 212) CABGþSVR (total n ¼ 360) LCTx (total n ¼ 510)
Variable n*
No. (%) or
mean ± SD n*
No. (%) or
mean ± SD n*
No. (%) or






Age (y) 386 64  10 212 65  9.4 360 61  9.5 510 58  9.5 <.0001
Female sex 386 67 (17) 212 61 (29) 360 67 (19) 510 71 (14) <.0001
Body mass index (kg$m2) 386 29  5.2 212 27  5.4 359 28  5.1 502 27  4.4 <.0001
Cardiac comorbidity
No. of systems diseasedy 386 211 356 459 <.0001
0 4 (1) 3 (1.4) 11 (3.1) 19 (4.1)
1 12 (3.1) 16 (7.6) 61 (17) 80 (17)
2 73 (19) 34 (16) 86 (24) 110 (24)
3 297 (77) 158 (75) 198 (56) 250 (54)
Coronary artery diseasey
Left main 386 129 (33) 210 63 (30) 355 50 (14) 420 99 (24) <.0001
LAD system 385 364 (95) 210 191 (91) 355 324 (91) 429 380 (89) .0002
LCx system 385 334 (87) 208 177 (85) 356 247 (69) 442 315 (71) <.0001
RCA system 384 351 (91) 210 190 (90) 355 256 (72) 446 355 (80) <.0001
Myocardial infarction 386 386 (100) 212 212 (100) 360 360 (100) 510 448 (88) <.0001
LV ejection fraction (%) 296 22  4.2 207 20  4.5 360 17  5.3 499 16  7.6 <.0001
MV regurgitation grade 385 212 359 498 <.0001
0 126 (33) 0 (0) 84 (23) 65 (13)
1þ 142 (37) 1 (0.47) 72 (20) 82 (16)
2þ 116 (30) 2 (0.94) 64 (18) 123 (25)
3þ 1 (0.3) 104 (49) 80 (22) 131 (26)
4þ 0 (0) 105 (49.5) 59 (16) 97 (19)
Ventricular arrhythmia
(ECG)
386 61 (16) 212 41 (19) 360 47 (13) 473 201 (42) <.0001
Clinical symptoms
NYHA functional class 386 212 360 500 <.0001
I 39 (10) 11 (5.2) 26 (7.2) 0 (0)
II 176 (46) 88 (42) 155 (43) 3 (0.6)
III 117 (30) 87 (41) 137 (38) 269 (54)
IV 54 (14) 26 (12) 42 (12) 228 (46)
Angina 381 210 353 28
Atypical 9 (2.4) 9 (4.3) 7 (2.0) 0 (0) .3
Rest pain 79 (21) 40 (19) 58 (16) 7 (25) .4
Unstable 106 (28) 48 (23) 73 (21) 13 (46) .005
Noncardiac comorbidity
Hypertension 373 298 (80) 205 153 (75) 357 239 (67) 488 317 (65) <.0001
Smoking 383 284 (74) 211 150 (71) 357 273 (76) 501 385 (77) .4
COPD 385 106 (28) 211 63 (30) 360 118 (33) 442 86 (19) .0002
Peripheral arterial disease 386 228 (59) 212 126 (59) 360 158 (44) 477 124 (26) <.0001
Treated diabetes 382 174 (46) 212 76 (36) 355 100 (28) 498 149 (30) <.0001
Stroke 386 43 (11) 212 15 (7.1) 360 36 (10) 485 252 (52) <.0001
BUN (mg$dL1) 382 22  11 209 26  13 352 22  11 502 33  19 <.0001
Bilirubin (mg$dL1) 322 0.68  0.53 180 0.85  0.66 318 0.76  0.53 492 1.4  1.2 <.0001
CABG, Coronary artery bypass grafting; MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation; SD, standard deviation;
LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; LV, left ventricular; MV, mitral valve; ECG, electrocardiogram;
NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; BUN, blood urea nitrogen. *Number of patients with data available. yFifty percent or greater
stenosis.
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fraction for early death and longer interval from myocardial
infarction to operation, complete heart block, left circumflex
coronary artery stenosis, and noncardiac comorbidities for
late death (Table 2). After CABGþSVR, unadjusted survivalThe Journal of Thoracic and Caat 1, 3, 5, and 9 years was 94%, 86%, 76%, and 55%, re-
spectively. Risk factors included lower ejection fraction and
higher Canadian Angina Class for early death and both car-
diac and noncardiac comorbidities for late death (Table 2).
After LCTx, unadjusted survival at 1, 3, 5, and 9 yearsrdiovascular Surgery c Volume 139, Number 2 285
FIGURE 1. Decision-support schema. I, Therapies applicable for ischemic cardiomyopathy. II, Survival comparisons of only applicable surgical therapies in
the decision-support model. EF, Ejection fraction; MI, myocardial infarction; CABG, coronary artery bypass grafting; MVA, mitral valve anuloplasty; SVR,
surgical ventricular restoration; LCTx, listing for cardiac transplantation; MR, mitral regurgitation; LVEDD, left ventricular end-diastolic diameter.
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Dwas 79%, 72%, 66%, and 54%, respectively. Risk factors
included older age, ventricular arrhythmia, and 3-system
coronary disease for early death and longer interval from
myocardial infarction to listing and both cardiac and noncar-
diac comorbidities for late death (Table 2). Of 510 patients in
the LCTx group, 94 died awaiting transplantation, all of
whom were included in the analysis; 54 were delisted be-
cause of recovery or destination therapy; and 348 underwent
transplantation.
Among the risk-factor models for each of the 4 therapies,
24 unique factors (Table 2) appeared, all of which were in-
corporated into our final decision-support models (Table
E3).
Model Validation
The number of deaths predicted by each training model
corresponded well (P> .1) with the observed number of
deaths in the 20% holdout sample (Table E4). Observed sur-286 The Journal of Thoracic and Cardiovascular Surgvival estimates after each therapy were well within confi-
dence limits of predicted survival, and the Brier score was
nearly always less than 0.25, both of which are indicative
of excellent prediction (Figure E2).
Survival Comparisons
Among the 1468 patients, only 1 therapy received was
deemed applicable in 420 (29%), 2 in 581 (40%), 3 in 357
(24%), and all 4 in 110 (7.5%). Of patients for whom more
than 1 therapy was considered applicable, 750 (51%) were
predicted to have better 5-year survival with a therapy other
than the one received (Figure 3), although the difference in sur-
vival ranged from trivial to large ( Figure E3). This was partic-
ularly true of CABGþMVA, for which survival was predicted
to be betterwithCABGalone in 133 (63%) patients forwhom
alternative therapies were considered appropriate. The highest
concordancewith treatment receivedwasCABGalone (72%)
and the lowest was CABGþMVA (15%).ery c February 2010
FIGURE 2. Time-related mortality after surgical therapies for ischemic cardiomyopathy. Each symbol represents a death positioned on a vertical axis by
using a Kaplan–Meier estimator, and vertical bars represent 68% confidence limits equivalent to 1 standard error. Solid lines are parametric survival es-
timates. CABG, Coronary artery bypass grafting; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation; MVA, mitral valve anulo-
plasty.
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Using the decision-support tool, patient-specific simulta-
neous solutions for time-related survival after those thera-
pies considered appropriate revealed procedures that
potentially could have maximized survival. Consider a 53-
year-old male patient with ischemic cardiomyopathy and
an anterior infarction 2 years ago with akinetic but viable
myocardium; an ejection fraction of 25%; a left ventricular
end-diastolic diameter of 6.5 cm; NYHA functional class IV
based on heart failure symptoms; MR grade 3þ; 3-system
coronary disease; and multiple noncardiac comorbidities.
Before survival is calculated, each therapy is evaluated for
applicability. For example, myocardial viability was as-
sessed and found adequate, and his severely stenotic coro-
nary arteries were considered suitable for CABG. His
moderately severe MR made CABGþMVA applicable, and
his greater than 6.0-cm left ventricular end-diastolic diame-
ter made CABGþSVR applicable. He was evaluated for
heart transplantation and found to have no contraindications.
Thus, for illustration, all 4 therapies were considered appli-
cable for this unusual combination of risk factors. As shown
in the Figure 4, A, scenario, all therapies were predicted to
yield different long-term prognoses, with LCTx having the
best survival and CABGþMVA the worst. A screenshot of
the strategic decision aid for this patient is shown in Figure 5.
We can then explore the consequences of altering the pa-
tient’s clinical profile, as detailed in Table E5. Five years later,
this same patient has an anterior aneurysm, left main disease,
and severe renal disease. His survival is predicted to be even
worse with CABGþMVA (Figure 4, B, scenario) but better
with CABGþSVR; CABG alone and LCTx are no longer ap-
plicable because of the absence of viable myocardium and se-The Journal of Thoracic and Cavere renal disease, respectively. If the patient does not have
MR, has viable myocardium without dyskinesis/akinesis,
and has severe 3-system coronary disease, then CABGþSVR
and CABGþMVA are no longer applicable, and CABG alone
is predicted to result in better survival than LCTx (Figure 4,C,
scenario). If the patient has the unusual combination of low
ejection fraction (15%), MR grade 4þ, and multiple cardiac
and noncardiac comorbidities, CABGþMVA is predicted to
maximize survival (Figure 4, D, scenario).
DISCUSSION
Principal Findings
Our predictive models, incorporating 24 routinely as-
sessed clinical and cardiac structural variables, reliably
demonstrate that each surgical therapy for ischemic cardio-
myopathy has a unique short- and long-term survival pattern
that is predictable but highly variable from patient to patient.
In general, CABGþMVA was associated with the lowest
5-year survival, and these patients in particular might
benefit from an alternative intervention. CABG alone,
CABGþSVR, and LCTx often had comparable long-term
outcomes, but CABG requires myocardial viability and
bypassable coronary arteries. It appears that more patients
with viability might benefit from a simple and safe procedure
(CABG alone) and that patients with more advanced NYHA
functional class symptoms of heart failure would have
improved long-term survival with LCTx.
Surgical Decision for Ischemic Cardiomyopathy
For more than 15 years, aggressive surgical treatment of
advanced ischemic cardiomyopathy has been advocated as
an alternative to transplantation. This study focused on therdiovascular Surgery c Volume 139, Number 2 287










NYHA functional class III/IV 1.4  0.58 .02 50
Stroke 1.5  0.50 .004 69
Late hazard phase
Older agey 0.52  0.16 .002 71
Treated diabetes 0.90  0.24 .0001 64
COPD 1.3  0.25 <.0001 94
Popliteal disease 0.73  0.26 .006 52
Higher cholesterolz 3.5  1.1 .002 76
CABGþMVA
Early hazard phase




0.019  0.0079 .02 58
Complete heart block 0.800  0.32 .01 57
LCx disease (70% stenosis) 0.69  0.30 .02 71
Insulin-treated diabetes 0.67  0.31 .03 65
Renal disease 1.1  0.32 .0008 98
Higher BUN{ 1.1  0.32 .0009 98
CABGþSVR
Early hazard phase
Lower LV ejection fractionx 1.8  0.800 .02 60
Higher Canadian Angina Class 0.77  0.36 .03 78
Late hazard phase
Lower LV ejection fraction# 0.76  0.28 .008 77
Atrial fibrillation 1.5  0.45 .001 62
Left main disease (any stenosis) 0.51  0.27 .05 90
RCA disease (50% stenosis) 0.705  0.32 .03 90
Aortic valve regurgitation 0.87  0.305 .004 57
Higher BUN{ 1.00  0.29 .0005 62
Lower hematocrit** 4.0  0.91 <.0001 77
Heart transplantation—at listing
Early hazard phase
Older ageyy 1.6  0.63 .01 54
Ventricular arrhythmia 0.39  0.200 .05 62
Three-system coronary diseasezz 0.69  0.21 .001 91
Higher BUNxx 0.060  0.012 <.0001 99




0.044  0.018 .01 75
Insulin-treated diabetes 1.2  0.55 .02 70
Aortic valve regurgitation 1.5  0.55 .007 83
Ventricular arrhythmia 1.2  0.62 .05 70
Peripheral arterial disease 1.5  0.59 .01 63
SD, Standard deviation; CABG, coronary artery bypass grafting; NYHA, New York
Heart Association; COPD, chronic obstructive pulmonary disease;MVA, mitral valve
anuloplasty; LV, left ventricular; MI, myocardial infarction; LCx, left circumflex cor-
onary artery; BUN, blood urea nitrogen; SVR, surgical ventricular restoration; RCA,
right coronary artery. *Percentage of times variable appeared in 1000 bootstrap analy-
ses. yExp(age/50), exponential transformation. z(100/cholesterol level), inverse trans-
formation. xLn(LV ejection fraction [%]), logarithmic transformation. k(Years from
MI to operation/3)2, squared transformation. {Ln(BUN), logarithmic transformation.
#(LV ejection fraction [%]/20)2, squared transformation. **Ln(hematocrit), logarith-
mic transformation. yyLn(age), logarithmic transformation. zzFifty percent or greater
stenosis in all LADs, LCxs, and RCAs. xx(BUN/20)2, squared transformation.
kk(Interval from MI to listing [years]/4)2, squared transformation.
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term survival data were available. Each has specific indica-
tions, but for a given patient, more than 1 of these might be
deemed appropriate.
MV intervention. The survival advantage of this surgical
intervention has been challenged. Tolis and colleagues11
and Mihaljevic and colleagues12 found no long-term sur-
vival advantage to adding MV repair to CABG in patients
with either moderate or severe ischemic MR, and Wu and
colleagues13 demonstrated that medical therapy yielded
similar survival to surgical intervention. Gorman and Gor-
man’s14 commentary on the article by Tolis and colleagues11
accurately states that the effect of MV intervention on
survival is minimal and prognosis is poor. Refining selection
of therapies for these patients with moderate or severe ische-
mic MR is urgently needed. Our model using simple clinical
variables suggests that in the presence of lower ejection frac-
tion and heart failure symptoms, therapies other than
CABGþMVA should be evaluated.
CABG alone and CABGþSVR. Most supporting evidence
for direct revascularization in patients with reduced left ven-
tricular function is derived from studies conducted in the
1970s and 1980s that predated modern surgical techniques,
devices, and medical therapies.15 Subsequent information
identified ischemic features less likely to respond to
CABG alone. Poor target-vessel quality,16 large ventricular
volume,17,18 and absence of myocardial viability19 were as-
sociated with worse survival, and our models show that after
CABG alone, patients who had atrial fibrillation and chronic
obstructive pulmonary disease experienced worse outcomes.
Reducing ventricular size to improve function makes theo-
retical sense,20 but modeling data suggest the equal possibil-
ity of worsening ventricular diastolic function.21,22 The
National Heart, Lung, and Blood Institute–funded Surgical
Treatment for Ischemic Heart Failure trial showed that con-
comitant addition of SVR to CABG alone resulted in re-
duced left ventricular volume, but did not reduce deaths or
hospitalizations for cardiac causes.23 Many of our simula-
tions revealed similar survival outcomes with CABG alone
or CABGþSVR. Subanalyses examining the relationships
of ventricular volumes to outcomes and the role of medical
therapy might elucidate these interactions.23
LCTx. Although survival after heart transplantation is
good, there is considerable mortality while awaiting trans-
plantation; 18% of our LCTx cohort died during this period.
Selecting patients who will be best served by transplantation
is difficult and becoming more so because 1-year survival of
status 2 patients is now equivalent to that of patients receiv-
ing a transplant.24,25 Our results should be viewed cautiously
because we did not incorporate all standard transplantation
criteria into our simulation of the complex decision-making
processes; specifically, most patients receiving alternative
therapies would not have been listed as status 1A or 1B.
Our models confirmed our clinical suspicion of whichery c February 2010
FIGURE 3. Percentage (and number of patients for each bar) of patients predicted to have the highest 5-year survival after therapy received (upward-pointing
bars) and those of patients predicted to have better 5-year survival with an alternative therapy (downward-pointing bars) for each therapy received. CABG,
Coronary artery bypass grafting; MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation.
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ternative. In older patients with renal dysfunction and other
heart failure symptoms, LCTx offered no survival advantage
over CABGþMVA or CABG alone.
Decision Support
Clinical decision making is a collaborative effort between
clinician and patient. For the clinician, the type of decision
support presented in this article tailors information on avail-
able therapeutic options to the patient in a manner that is un-
derstandable and unbiased. With decompensating patients
who have a complex clinical makeup, it becomes difficult
for the clinician to discern the therapy that maximizes sur-
vival and to recognize subtle changes that can have long-
term ramifications. The tool presented can be used during
consultation to illustrate the tradeoffs of specific therapies
and provide a better medium for informed consent, allowing
a better collaborative approach to decision making. It can beThe Journal of Thoracic and Caused to determine whether a patient is less likely to benefit
from alternative treatments and to facilitate formulating
risk-reduction strategies.
For the patient, decision making involves not only giving
consent to a clinician’s recommendation but also evaluating
and appreciating the tradeoffs of short-term risk and long-
term gain. Although survival is ultimate, a patient also needs
to take into consideration effects of alternative therapies on
quality of life. Increasingly, medical decisions are also being
scrutinized on the basis of short- and long-term costs of care
to society, often without considering the offsetting contribu-
tions these patients give back to society.26
Clinicians are becoming aware of the difficulty of assim-
ilating the multitude of factors and their complex interplay in
formulating therapeutic recommendations for their patients.
Unknowingly, these recommendations are made with many
biases, in which surgeons rely on past experience with sim-
ilar cases. Practically, they often use simple heuristic rulesrdiovascular Surgery c Volume 139, Number 2 289
FIGURE 4. Survival predicted after each of 4 therapies for 4 different scenarios (see Table E5 for details). Top left, Scenario A; top right, scenario B; bottom
left, scenario C; bottom right, scenario D. Dashed lines represent artificial survival curves for therapies not deemed applicable for the given patient’s char-
acteristics. LCTx, Listing for cardiac transplantation; CABG, coronary artery bypass grafting; SVR, surgical ventricular restoration; MVA, mitral valve anu-
loplasty.
FIGURE 5. Java-based user interface for clinical strategic decision support. Results for scenario A in Figure 4 are shown. CABG, Coronary artery bypass
grafting; MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation. Used by permission of Cleveland
Clinic.
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example, a surgeon might recognize the risk of renal failure
if the creatinine value is 1.5 times the baseline value, but will
not differentiate it as a continuous variable. Cognitive capac-
ity limitations in human subjects restrict detection of strong
correlations when the number of variables exceeds 7  2
items.29 Our model has been developed from more than 75
preoperative variables in addition to multiple transforma-
tions of each continuous variable, a difficult feat for
a surgeon to fully assimilate. Impeding accurate recommen-
dations further, individuals rely on fewer cues for decision
making when information load is high or time constraints
are present.30
Thus, clinicians increasingly rely on risk-assessment tools
to guide therapies, including the EuroSCORE,31 the Society
of Thoracic Surgeons risk models,32 the Seattle Heart Fail-
ure Model,33 and the preoperative risk score for mortality
after left ventricular assist device surgery.34 These and our
‘‘cognitive prosthesis’’ tool are not meant to replicate or
replace surgeons’ cognition through prediction models35
but rather to synergistically augment and extend their
capabilities.36
Study Limitations
This is a single-institution clinical study. Surgical proce-
dures analyzed were performed over many years, during
which all clinical variables were not uniformly collected.
We did not address the role of concomitant medical or de-
vice therapies, stipulate all standard transplantation criteria,
or measure the value of sequential therapies, such as CABG
before transplantation. Assessment of myocardial viability,
if available, is an important and early decision point that
must be incorporated in the decision-making process for ap-
plicability of therapies; however, because of the paucity of
data, we could not ascertain whether it influenced survival.
The study’s primary end point was all-cause time-related
mortality, and we considered only maximizing survival.
We did not measure quality-adjusted life years, costs, ad-
verse cardiac events, readmissions for heart failure, or im-
provement in functional class, all of which might be
important outcomes from the patient’s, payer’s, and soci-
ety’s perspectives. From an analytic perspective, the number
of patients undergoing each therapy was modest, limiting the
number of risk factors that could be identified reliably. Fur-
thermore, we used only 1 holdout (test) sample; more so-
phisticated methods to calculate prediction error are
becoming available. Finally, these and all models of long-
term survival suffer from the rapid change of medical and
surgical therapies, with difficult-to-quantify important incre-
mental advances.
Clinical Implications
Optimal treatment of patients with advanced heart failure
caused by ischemic heart disease needs to be assisted byThe Journal of Thoracic and Careal-time clinical decision-making tools. We envision, in
the not-too-distant future, models that will predict survival
with both medical and surgical therapies, left ventricular as-
sist device support as bridge or destination therapy, and car-
diac transplantation.
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Dr Curtis G. Tribble (Gainesville, Fla). I have been handing
out Dr Bruce Lytle’s single–authored essay on this subject that
was published in the Annals of Thoracic Surgery about 5 years
ago to most of my junior house officers and students ever since
he wrote it. It is a great article for anybody who would like to
read about his thoughts at that time. His last sentences in that article
state that (1) coronary artery bypass surgery is best for most of these
patients with ischemic cardiomyopathy, (2) we do not know very
much about any of the other options, and (3) the other options
should be studied. Today’s article presented by Mr Yoon is obvi-
ously an attempt to address that charge.
I have to admit, as a former English major, that I was a bit dis-
tracted and even fascinated by the language of this article, such292 The Journal of Thoracic and Cardiovascular Surgas the ‘‘split–sample holdout.’’ I am not going to ask you this, Dus-
tin, but don’t you think that sounds more like a poker game than
a statistical test? Other terms were equally interesting, such as the
‘‘parsimonious variable selection,’’ ‘‘the bagging bootstrap aggre-
gation,’’ and my favorite term in the article, ‘‘the cognitive prosthe-
sis tool.’’ But all kidding aside, I did round up a real statistician and
ask for some help in understanding all these terms, and I did learn,
as I would have expected, that all these terms are not only real but
quite valid statistical strategies.
I will also say that it is obvious that this study was a good-faith
effort to answer Dr Lytle’s earlier call for more clarity on the op-
tions for ischemic cardiomyopathy. There are lots of patients, there
are hard end points, and there, indeed, are valid statistical strategies.
However, one of my difficulties in thinking about this article is that
clearly not all the options are truly available to all the patients, and,
presumably, some thoughtful person made the original choice
based on literally tens if not hundreds of bits of data, surely some
of which are unknown to the later reviewer and, thus, difficult to
study.
So to think more specifically about some of the numbers, it
seems to me that although 75% of the total group of 1321 patients
were well served by coronary artery bypass alone (n ¼ 556) or by
transplantation (n ¼ 423), less than 4% (n ¼ 50) were well served
by mitral valve repair combined with coronary bypass. I think this
is a sobering assertion and leads me to my one question for you,
Dustin, that you might have some insight into from your study
along with other recent studies from your institution, such as
Mark Gillinov’s article presented at this meeting last year compar-
ing mitral valve repair and mitral valve replacement in older pa-
tients, in which survival was not altered by the technique of
treating the mitral valve.
Here is my question. Given that your model suggests that mitral
valve repair should be done in so few patients with ischemic mitral
regurgitation, do you think that it is possible that the patients with
ischemic mitral valve regurgitation would have been better served
with an mitral valve replacement instead of a mitral valve anulo-
plasty if this were done with the techniques of modern cardiac pro-
tection and chordal preservation, or is it the sense of you and your
colleagues at the Cleveland Clinic that the regurgitant mitral valve
in the setting of ischemic cardiomyopathy is best treated medically
in the vast majority of cases?
Mr Yoon. Thank you very much for your comments and your
question, Dr Tribble.
When we went back and analyzed alternative survival compar-
isons for CABG alone, CABG with concomitant SVR, and trans-
plantation therapies, we found that mitral valve anuloplasty was
recommended as the best therapy to optimize survival less than
2% of the time. As you say, these are sobering statistics, and I
think they may provide some insight into which options have
the best long-term outcomes. Mitral valve anuloplasty may not
be the best option for these patients with ischemic mitral valve
etiology.
In terms of Dr Gillinov’s paper presented here last year, he
looked at 195 propensity-matched pairs undergoing replacement
versus repair for degenerative mitral valve disease and found no
major survival difference between these 2 groups. Neither mitral
valve repair nor replacement emerged as a risk factor that affected
overall survival.ery c February 2010
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DWe think that a common thread in all these studies is that, in
these sicker patients with ischemic cardiomyopathy and multiple
comorbidities, prognosis is poor whether you do replacement or re-
pair. I believe that it will require a randomized trial to further elu-
cidate these types of outcomes. My mentor, Dr Blackstone, has
informed me that in July, the Cardiac Surgery Network plans to
conduct a randomized trial looking specifically at these outcomes,
at moderate and severe mitral regurgitation, and at the effects of
repair versus replacement. The results will hopefully settle some
of the controversy surrounding treatment options.
Dr Paul Kurlansky (Miami, Fla). This is a very provocative
and interesting study. I look forward to the complete article to try
to understand it better. I would like to exercise a word of caution,
though, and perhaps it is related to the number of patients included
and the number of variables that were available to you. In the exam-
ple that you presented, a patient who had a certain risk-factor profile
with lifestyle problems and smoking, lifestyle problems that led to
diabetes as well as cigarette smoking, put him into the transplanta-
tion category. I think that shows probably one of the shortcomings
of this approach because likely somebody who has lifestyle prob-
lems and smoking might not be an ideal candidate for transplanta-
tion and might not be accepted for transplantation.
Therefore, I think we wind up with a situation in which our clin-
ical judgment might be even better than what the figures would sug-
gest, and I was sort of wondering how you might solve some of
these problems. Perhaps it might be wiser to view this sort of study
as hypothesis generating rather than definitive.
Mr Yoon. Thank you very much for your comment, Dr Kurlan-
sky. I think your point is well taken, and it is in fact the reason we
used the term ‘‘decision support tool’’ rather than ‘‘decision mak-
ing tool.’’ In complex, real-world scenarios, I think a tool like this
can synergistically augment a surgeon’s capabilities by allowing
not just 1 or 2 clinical variables to be taken into account when rec-
ommending the optimal surgical therapy but rather 3, 4, 5, or, in our
case, hundreds of preoperative variables and their transformations.
This is difficult for surgeons to fully assimilate, and studies have
shown that clinicians usually think of the average result when it
comes to variables, and not necessarily the magnitude. A support
tool can help tremendously in this aspect.
In terms of applicability of each therapy, I think your point is
also well taken in that not all of our patients were eligible for every
treatment option. We tried to correct for this by setting eligibility
criteria for our patient population. For example, to be eligible for
SVR, a patient had to have anterior akinesia or dyskinesi, and
also a left ventricular end diastolic diameter greater than 6 cm. In
fact, the STICH trial eligibility to enter the study was based on an-
terior akinesia or dyskinesia amenable to SVR and an ejection frac-
tion of 35% or less. For transplantation, our patients had to be in
New York Heart Association functional class III or IV, be less
than 70 years old, and have a serum creatinine level of less than
1.7 mg/dL. These broad criteria were set up to include all possible
choices that an individual could have and not necessarily that they
should undergo that particular surgery. The guidelines are just
that—a possible path. The surgeon would make the final decision
based on all available clinical information, imaging results, and fi-
nal inspection in the operating room.
Dr John V. Conte, Jr (Baltimore, Md). I would like to congrat-
ulate you on a flawlessly presented article, and I would like toThe Journal of Thoracic and Cacommend your mentors and co-authors on helping you to prepare
such a nice presentation. I know how much work it takes, and I
think this kind of mentoring is what we need to do more of in
our specialty, particularly allowing junior members of our profes-
sion to present at national meetings.
The one comment I would like to make other than congratulating
you and your co-authors is that this is a very intriguing article; how-
ever, the hypothesis does not help many people with decision mak-
ing in the real world. The reality is we do not have transplantation as
an option that is readily available at the times that we often would
like for such patients, and also your inclusion of patients undergo-
ing SVR who had an infarction as recently as 30 days also does not
correlate with what we would generally recommend. We would not
perform that operation for most patients who have had an infarction
that recently.
Those limitations being noted, I think it does provide questions
for us when we are selecting options for our patients, and again, I
want to congratulate you on a nice job.
Mr Yoon. Thank you very much, Dr Conte. As part of our
inclusion criteria, all patients in the study had a myocardial infarc-
tion greater than 30 days before surgery. In our SVR population,
the median time between infarction and surgery was 3 years, so
your point is valid. The decision to pursue SVR includes MRI
studies, viability, and final inspection in the operating room,
some factors that we did not and cannot incorporate into our
models. Also, you are absolutely right that fewer than 10% of el-
igible recipients actually receive a heart transplantation. This is
the reason we need to evaluate other treatment options for cardio-
myopathy and know, as best as possible, the risks and survival
benefits of these alternative treatments. Clearly, all the issues
you raise are important.
DrCharles C. Canver (Riyadh, Saudi Arabia). This is a very in-
triguing article. When I began to listen, I was hoping that you were
going to come up with a model, almost a calculator, that would help
to solve this complex problem.As you know, ischemic cardiomyop-
athy is a syndrome that cannot be caused by a single process. Unfor-
tunately, this model is not capable of really answering the clinical
questions. In reality, the decision is made by the use of many tests
that assesses the viability of the myocardium in light of the patient’s
symptoms. Furthermore, I had difficulty accepting that your
51-year-old patient with a 4þMR and 10% ejection fraction could
be best treated with CABG alone. In the actual clinical setting, I
do not think anybody would tackle that problem with CABG alone.
I am very intrigued by young individuals, such as yourself, who
are trying to bring new preoperative calculation methods to help us
make a better decision in complex clinical dilemmas. Although that
is a very nice thing to do, I am still skeptical. Your clinical model
certainly does not address the real clinical issues. However, I do
want to congratulate you for your nice work.
Mr Yoon. Again, with this decision support tool, we have made
small but significant steps toward a clinical tool that can be
accurately and reliably used in the clinical setting. In the future,
we will continue trying to elucidate these many and variable factors
that surgeons must deal with in the real clinical world. We also
anticipate prospective and external validation of our tool and will
take steps for its generalizability to the outside population. Thank
you for your comments, Dr Canver; I will definitely keep them in
mind.rdiovascular Surgery c Volume 139, Number 2 293
APPENDIX 1. Variables used in analyses
Demographic: Age (y), sex, weight (kg), height (cm), body surface area (m2), body mass index (kg$m2)
Symptoms: New York Heart Association functional class (I–IV), Canadian Angina Class (0–4), atypical angina, angina (rest pain, unstable angina), clinical
symptoms (dyspnea, dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, peripheral edema, pulmonary edema—and their timing (history,
current, both history and current)
Ventricular dysfunction: Degree of left ventricular dysfunction (1 ¼ none, 2 ¼ mild, 3 ¼ moderate, 4 ¼ severe), ejection fraction (%), interval from date of
most recent myocardial infarction to date of operation
Valve pathology: Aortic valve stenosis (presence and grades 0–5), aortic valve regurgitation (presence and grades 0–4þ), mitral valve regurgitation (grades
0–4), tricuspid valve regurgitation (grades 0–4)
Coronary anatomy: Left main trunk disease (maximum% stenosis), left anterior descending coronary artery system disease (maximum% stenosis), right
coronary artery system disease (maximum% stenosis), left circumflex coronary artery system disease (maximum% stenosis)
Other cardiac comorbidity: Atrial fibrillation, family history of ischemic heart disease, complete heart block, ventricular arrhythmia
Noncardiac comorbidity: Treated diabetes, insulin-treated diabetes, hypertension, history of smoking, carotid disease, popliteal disease, peripheral arterial
disease, creatinine (mg$dL1), creatinine clearance (mg$dL1), blood urea nitrogen (mg$dL1), bilirubin (mg$dL1), hematocrit (%)
Experience: Date of operation (years from January 1, 1997, to operation or listing)
METHODS
Data Analysis
Survival was estimated nonparametrically by using the Kaplan–Meier
method and parametrically by using a multiphase hazard model.E1 The para-
metric model was used to resolve the number of phases of instantaneous risk
of death (hazard function) and to estimate shaping parameters. (For addi-
tional details, see http://www.clevelandclinic.org/heartcenter/hazard.)
Model development. A split-sample (holdout) method was used to
create a random 80% training and 20% test data set for each surgical therapy.
By using only the training data sets, a parsimonious risk-factor model for mor-
tality was created for each therapy. For these, multivariable analysis of preop-
erative variables (Appendix 1) was performed in the multiphase hazard
function domain. Therapy-specific analyses were performed in part because
thehazard functionswere of different shapes (FigureE1)but primarily asa stra-
tegic approach because not all therapies are applicable to each patient.
Parsimonious variable selection used bagging (bootstrap aggrega-
tion)E2,E3 and 1000 bootstrap samples, with a P value criterion for retention
of variables in automated stepwise variable selection of .05. Frequency of
occurrence of variables identified in these analyses indicated the reliability
of each variable’s association with mortality at a P value of .05 or less. Vari-
ables with 50% or more reliability were retained in the parsimonious model.
Risk factors identified in any of the 4 models were then incorporated
into a semisaturated model for each therapy. After validation, as de-
scribed in the text that follows, the entire data set was used to generate
the 4 final models from which the strategic decision aid was constructed
(Table E5).
Group comparisons with propensity scores were inappropriate because
the study’s purpose was to identify risk factors for each treatment and pre-
dict survival for an individual’s personal characteristics and condition.E4
Propensity score techniques are a substitute for randomized trials and ad-
dress, just as randomization does, selection bias.E5,E6 Identical to a random-
ized trial, they focus on group comparisons of outcome (in well-matched
patients). These methods are not used to analyze the full spectrum of
patients but rather compare the subset of patients with overlapping charac-
teristics.
Model validation. The 4 semisaturated models were used to predict
survival of each patient in the holdout sample (20% of each therapy).
Two validation criteria were used: (1) conservation of events, comparing
with a c2 goodness-of-fit test the number of observed deaths versus pre-
dicted deaths calculated from estimated cumulative hazard at the end of
each patient’s follow-up,E7 and (2) comparison of observed versus predicted
survival. For the latter, theweightedBrier score,E8which provides ameasure
of discrepancy between observed and expected survival in the holdout sam-
ple, was estimated at each observed event time point. The smaller the Brier
score, the better the prediction. A Brier score of 0.25 indicates no better than
random prediction; hence we use 0.25 as the reference value.
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FIGUREE1. Instantaneous risk of death (hazard function after each surgi-
cal therapy for ischemic cardiomyopathy). A, Risk of death to 9 years. B,
Risk of death within first year. Solid lines are parametric estimates.
CABG, Coronary artery bypass grafting; SVR, surgical ventricular restora-
tion; MVA, mitral valve anuloplasty; LCTx, listing for cardiac transplanta-
tion.
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FIGURE E2. Graphic comparisons of model validation for each therapy. Solid lines enclosed within dashed 68% confidence limits are predicted survival
estimates, symbols and vertical 68% confidence bars are Kaplan–Meier estimates of actual survival in the 20% holdout samples, and numbers in parentheses
represent patients remaining at risk. Dots are Brier scores at each event time point, with the 0.25 line as the reference value below which predicted and
observed survival are deemed appropriate. CABG, Coronary artery bypass grafting; SVR, surgical ventricular restoration; MVA, mitral valve anuloplasty;
LCTx, listing for cardiac transplantation.
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FIGURE E3. Cumulative 5-year survival difference between therapy received and therapy maximizing survival. Differences were calculated only for pa-
tients for whom an alternative therapy to the one received was predicted to provide greater 5-year survival. CABG, Coronary artery bypass grafting; SVR,
surgical ventricular restoration; MVA, mitral valve anuloplasty; LCTx, listing for cardiac transplantation.
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TABLE E1. Myocardial viability by surgical therapy
CABG alone
(total n ¼ 386)
CABGþMVA
(total n ¼ 212)
CABGþSVR
(total n ¼ 360)
LCTx
(total n ¼ 510)
Variable n*
Mean ± SD or
15th/50th/85th
percentiles n*
Mean ± SD or
15th/50th/85th
percentiles n*
Mean ± SD or
15th/50th/85th
percentiles n*






Transmurality scorey 28 0/2/6 25 0/2/6.2 92 2/6/8 8 5/8/10 <.0001
Total scar scorez 28 1.04  0.71 25 1.1  0.84 92 1.8  0.63 8 2.4  0.52 <.0001
Dobutamine echocardiography
Transmurality scorex 33 8.1  2.4 14 7.6  3.6 52 8.6  2.3 12 8.7  4.3 .2
Total scar scorek 33 2.2  0.41 14 2.1  0.70 52 2.2  0.40 12 2.3  0.77 .2
FDG–PET
Transmurality score{ 5 0/2/6.5 6 0/0/5 1 1.2 3 0/1.5/3.6 .7
Total scar scorez 5 0/0.71/1.6 6 0/0.47/1.6 1 0 3 0.12/0.42/0.9 .5
SPECT
Transmurality score# 4 0/0/2 3 0/0/1.6 0 — 4 0/0/0 .4
Total scar scorez 4 0/0/0.51 3 0/0/0.55 0 — 4 0/0/0.07 .7
Thallium
Transmurality score** 3 0/1/2 2 0/1/2 0 — 2 0/1/2 .4
Total scar scorez 3 0/0.21/0.54 2 0/0.21/0.54 0 — 2 0/0.21/0.54 .7
Patients with 1 viability study 84 53 179 33
CABG, Coronary artery bypass grafting; MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation; SD, standard deviation;
CMR, cardiac magnetic resonance; FDG–PET, fluorodeoxyglucose positron emission tomography; SPECT, 99-mTc-single photon emission computed tomography. *Number
of patients with data available. yNumber of segments with a CMR segmental scar score of 3 or 4. zSummed segmental scar scores/patientO 17 (reflecting damage/patient). xNormal
¼ 0, mildly hypokinetic ¼ 1, severely hypokinetic ¼ 2, akinetic ¼ 3, dyskinetic/aneurysmal ¼ 4. kSummed segmental scar scoresO 16 (reflecting damage/patient). {Number of
segments with an FDG–PET segmental scar score of 3 or 4. #Number of segments with an SPECT segmental scar score of 3 or 4. **Number of segments with a thallium segmental
scar score of 3 or 4.































Respiratory insufficiency 29 (7.5) 25 (12) 33 (9.2) 47 (14) .04
IABPz 14 (3.6) 21 (9.9) 31 (8.6) 19 (5.5) .006
Return to OR for bleeding 12 (3.1) 9 (4.2) 14 (3.9) 39 (11) <.0001
Septicemia/sepsis 8 (2.1) 11 (5.2) 21 (5.8) 43 (12) <.0001
Stroke 6 (1.6) 3 (1.4) 3 (0.83) 6 (1.7) .8
Myocardial infarction 1 (0.26) 0 (0) 2 (0.56) 0 (0) .4
Renal failure 5 (1.3) 10 (4.7) 5 (1.4) 16 (4.6) .004
Length of stay (d)
ICU 1/2/4 1/3/6 1/2/6 2/3/8 <.0001
Postoperative 5/7/12 6/9/19 6/9/17 9/14/26 <.0001
Hospital 6/10/19 7/14/26 7/12/23 13/32/83 <.0001
CABG, Coronary artery bypass grafting;MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; CL, confidence limits; IABP, intra-aortic balloon pumping; OR, op-
erating room; ICU, intensive care unit. *Secondary end points were in-hospital complications, which were defined according to the Society of Thoracic Surgeons National Adult
Cardiac Database (see http://www.ctsnet.org/file/rptDataSpecifications252_1_ForVendorsPGS.pdf). yThree hundred forty-eight of 510 listed patients received a heart transplant.
zIntraoperative and postoperative.
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TABLE E3. Incremental risk factors for death by surgical management group: Semisaturated model
CABG alone
(total n ¼ 386)
CABGþMVA
(total n ¼ 212)
CABGþSVR
(total n ¼ 360)
LCTx



















Age* 0.94  1.6 .6 11  5.4y .04 0.02  0.43 >.9 1.5  1.1 .2
NYHA functional
class III/IV
1.7  0.69 .01 26  9146 >.9 1.3  0.71 .07 11  73 .9
LV ejection
fractionz
0.59  1.4 .7 6.1  3.1 .05 2.1  0.81 .008 0.62  0.55 .3
Canadian Angina Class 0.100  0.22 .6 0.400  0.51 .4 0.53  0.24 .03 0.019  0.16 .9
Ventricular arrhythmia 0.17  0.68 .8 18  1829 >.9 0.404  0.82 .6 0.56  0.42 .2
Three-system coronary
disease
0.17  0.53 .7 1.1  1.6 .5 0.39  0.63 .5 0.94  0.43 .03
Previous stroke 1.3  0.61 .03 7.4  3.1 .01 1.5  0.68 .02 1.3  0.51 .01
BUNx 0.011  0.094 .9 1.4  1.01 .2 0.14  0.074 .05 0.088  0.021 <.0001
Bilirubin 0.19  0.31 .5 1.2  0.74 .09 0.39  0.51k .4 0.53  0.12 <.0001
Late hazard phase
Complete heart block 0.26  0.64 .7 0.48  0.39 .2 0.92  0.53 .08 0.44  0.34 .2
Ventricular arrhythmia 0.300  0.32 .4 0.51  0.31 .1 0.50  0.42 .2 0.55  0.24 .02
COPD 1.3  0.29 <.0001 0.38  0.29 .9 0.068  0.28 .8 0.21  0.29 .5
Renal disease 0.57  0.42 .2 0.94  0.38 .01 0.59  0.76 .4 0.51  0.25 .05
Age{ 0.42  0.19 .03 0.049  0.24 .8 0.36  0.26 .2 0.050  0.21 .8
LV ejection
fraction#
0.27  0.34 .4 0.103  0.33 .8 0.94  0.32 .004 0.030  0.12 .8
Atrial fibrillation 0.71  0.58 .2 0.17  0.45 .7 1.1  0.500 .03 0.14  0.23 .5
Left main disease
(any stenosis)
0.015  0.31 >.9 0.16  0.28 .6 0.59  0.300 .05 0.44  0.25 .08
RCA disease (50%
stenosis)
0.68  0.49 .2 0.404  0.52 .4 0.65  0.36 .07 0.36  0.31 .2
LCx disease (70%
stenosis)
0.049  0.31 .9 0.71  0.35 .04 0.062  0.29 .8 0.083  0.25 .7
AV regurgitation 0.300  0.37 .4 0.0038  0.38 >.9 1.02  0.33 .002 0.96  0.25 .0001
Interval from MI to
operation/listing**
0.21  0.12 .08 0.021  0.0091yy .02 0.22  0.14zz .1 0.016  0.011yy .2
Popliteal disease 0.77  0.32 .02 0.11  0.33 .7 1.02  0.52 .05 0.29  0.35 .4
Treated diabetes 0.68  0.31 .03 0.0086  0.37 >.9 0.075  0.37 .4 0.66  0.29 .02
Insulin-treated diabetes 0.29  0.35 .4 0.73  0.44 .1 0.64  0.47 .2 0.24  0.36 .5
Cholesterolxx 3.5  0.11 .002 0.56  0.74 .4 1.1  0.92 .2 0.504  0.36 .2
BUNkk 0.26  0.32 .4 1.3  0.35 .0004 0.78  0.34 .02 0.15  0.26 .6
Peripheral arterial disease 0.096  0.29 .7 0.18  0.34 .6 0.41  0.29 .1 0.600  0.24 .01
Hematocrit{{ 13  38## .7 1.3  0.93 .2 4.6  1.02 <.0001 2.6  0.704 .0003
CABG, Coronary artery bypass grafting; MVA, mitral valve anuloplasty; SVR, surgical ventricular restoration; LCTx, listing for cardiac transplantation; SE, standard error; NYHA,
New York Heart Association; LV, left ventricular; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; RCA, right coronary artery; LCx, left circumflex cor-
onary artery; AV, atrioventricular; MI, myocardial infarction.
*Ln(age), logarithmic transformation. y(50/age), inverse transformation. zLn(ejection fraction), logarithmic transformation. x(BUN/20)2, squared transformation. kLn(bilirubin),
logarithmic transformation. {Exp(age/50), exponential transformation. #(Ejection fraction/20), squared transformation. **(4/[interval from MI to operationþ1]), inverse transfor-
mation. yy(Interval from MI to operation/4)2, squared transformation. zzLn(interval from MI to operationþ1), logarithmic transformation. xx(100/cholesterol), inverse transforma-
tion. kkLn(BUN), logarithmic transformation. {{Ln(hematocrit), logarithmic transformation. ##(1/hematocrit), inverse transformation.
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TABLE E4. Model validation using the conservation-of-events
method
No. of deaths
Surgical therapy Observed Predicted P value
CABG alone 22 25.5 .4
CABGþMVA 11 12.1 .7
CABGþSVR 15 14.5 .9
LCTx 31 24.7 .14
CABG, Coronary artery bypass grafting;MVA, mitral valve anuloplasty; SVR, surgical
ventricular restoration; LCTx, listing for cardiac transplantation.
















0 0 0 1
RCA disease (50%
stenosis)
0 0 1 1
Left main disease (any
stenosis)
1 1 0 1
Three-system coronary
disease
0 0 1 1
LV ejection
fraction (%)
25 25 25 25
Interval from
MI to operation (y)
2.1 5 2.1 2.1
Atrial fibrillation 0 1 1 1
Aortic valve
regurgitation




1 1 1 1
Canadian Angina Class 4 4 4 4
Complete heart block 1 1 0 0
Ventricular arrhythmia 0 0 0 1
Noncardiac comorbidity
COPD 1 1 1 1
Treated diabetes 0 0 0 0
Insulin-treated diabetes 0 0 0 0
Stroke 1 1 1 1
Popliteal disease 0 0 0 0
Renal disease 0 1 1 0
BUN (mg$dL1) 14 14 14 14
Cholesterol (mg$dL1) 100 100 100 100
Bilirubin (mg$dL1) 0.8 1 1 1
Hematocrit (%) 40 40 40 40
LCx, Left circumflex coronary artery; RCA, right coronary artery; LV, left ventricular;
MI, myocardial infarction; NYHA, New York Heart Association; COPD, chronic
obstructive pulmonary disease; BUN, blood urea nitrogen.
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